Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289098 | 0.91 | GSK3B (0.51) | KMT2ATDP1GSK3BL3MBTL1POLB | |
| SCHEMBL13120549 | 0.89 | GSK3B (0.66) | KMT2ATDP1GSK3BL3MBTL1POLB | |
| SCHEMBL13289389 | 0.88 | GSK3B (0.53) | KMT2ATDP1GSK3BPOLBCHEK1 | |
| SCHEMBL13288942 | 0.82 | GSK3B (0.53) | GSK3BPOLBCHEK1 | |
| SCHEMBL13288944 | 0.82 | GSK3B (0.48) | KMT2ATDP1GSK3BPOLBNPC1 | |
| SCHEMBL13289383 | 0.82 | GSK3B (0.52) | TDP1GSK3BCHEK1 | |
| SCHEMBL13120600 | 0.81 | GSK3B (0.62) | KMT2ATDP1GSK3BL3MBTL1POLB | |
| SCHEMBL13289102 | 0.81 | GSK3B (0.50) | GSK3BCHEK1 | |
| SCHEMBL13289113 | 0.81 | GSK3B (0.51) | GSK3BCHEK1 | |
| SCHEMBL13120532 | 0.81 | GSK3B (0.66) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |